Recently polymer purchased from PolySciTech (www.polyscitech.com) (Polyvivo AK09
mPEG-P(DL)La) was utilized to generate a nanoparticle system for delivery of
docetaxel to pancreatic cancer. Read more: Gupta, R., D. Cvetkovic, C. M. Ma,
and L. Chen. "Targeted Approach for Prostate Cancer Treatment: Synthesis
and Characterization of Docetaxel-Loaded Perfluorocarbon Nanodroplets." J
Cancer Sci Clin Oncol 1, no. 1 (2014): 102. http://www.annexpublishers.com/articles/JCSCO/volume-1-Issue-1/Targeted-Approach-for-Prostate-Cancer-Treatment-Synthesis-and-Characterization-of-Docetaxel-Loaded-Perfluorocarbon-Nanodroplets.pdf
“Abstract: The purpose of this study is to synthesize and
characterize nanodroplets, loaded with docetaxel for treatment of prostate
cancer under MR-guided focused ultrasound. Water insoluble docetaxel
encapsulated in nanodroplets is expected to be delivered into tumors with
greater efficiency while minimizing drug related systemic toxicities when used
in combination with focused ultrasound. The sequence of our studies toward
development and characterization of docetaxel-loaded nanodroplets is as
follows. First, we developed methods for synthesis of ultrasound-responsive,
docetaxel-loaded nanodroplets (Doc-nd) by a solid dispersion technique.
Secondly, we characterized Doc-nd by its morphology and size distributions
using a dynamic light scattering (DLS) method. To check the consistency of the
data obtained from DLS, size distribution was also studied using an independent
technique by analyzing bright field microscopy images of Doc-nd in software
ImageJ. Thirdly, we studied the encapsulation efficiency and the release
kinetics of docetaxel from Doc-nd in phosphate buffer saline. Finally, we
performed in vitro cytotoxicity studies using a human prostate cancer cell line
(LNCaP). Our data showed that peak sizes of spherical Doc-nd were 222±15 nm.
These sizes favor passive accumulation into most tumors thus potentially
increasing localized docetaxel concentration. A high encapsulation efficiency
of 93.70% was obtained for Doc-nD. The release kinetics studies showed that
docetaxel was released from Doc-nd in a three- staged release pattern with an
initial release of 30% in one hour followed by a 50% release until 12h and an
85% release after three days. In vitro cytotoxicity studies using LNCaP cells
indicated a time-dependent cytotoxic profile and verified encapsulation of
docetaxel in the nanodroplets. Our study
suggested that Doc-nd may have the potential for treating prostate
cancer with an improved therapeutic ratio when combined with MR-guided focused ultrasound. Keywords: Docetaxel; Perfluorocarbon
Nanodroplets; Ultrasound; Prostate Cancer”
No comments:
Post a Comment